By Bethany Wales Biotech firm Bivictrix Therapeutics is the latest company to exit the London Stock Exchange’s AIM market, citing difficulties in raising funds compared to its privately-owned competitors. The company, which is headquartered in Macclesfield, said it would not be able to raise enough capital to advance its medication to a clinical trial via London’s junior market and that its listed-status was limiting its ability to explore more favourable funding opportunities with a US investment bank. Bivictrix added that it didn’t believe its current market capitalisation reflected “the pos…